CV301

AXP000180.1 · Cancer vaccine

Platform
MVA-BN prime, fowlpox boost
Targets
CEACAM5; MUC1
Originator
Bavarian Nordic
Sponsor
Bavarian Nordic

Names

NameTypeSource
CV301preferred name, codecurator, ncit
CV301-V/Fcodencit
CVAC-301codencit
FPV-CV301codencit
MVA-BN-CV301codencit
PANVAC ambiguoussynonymncit

Virus

Role
Vaccine vector
Family
Poxviridae
Virus
vaccinia virus (NCBI Taxonomy 10245)
Strain
MVA-BN prime; fowlpox (FPV-CV301) boost
Replication
non replicating
Modifications
CEA, MUC-1 and TRICOM cassettes in MVA-BN; fowlpox boost with the same cassette
Transgenes
CEACAM5, MUC1, CD80, ICAM1, CD58
Route
subcutaneous
Source
evidence

Cross-references

NCI Thesaurus
C131129

Approvals

No regulatory approval recorded.

Clinical trials (7)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT04574583Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)CompletedPhase 1/22020-11-242023-02-0712Metastatic Cancer; Solid Tumors
NCT04491955Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal CancersCompletedPhase 22020-09-222022-10-2532Colorectal Cancers; Small Bowel Cancers
NCT03628716CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder CancerCompletedPhase 22018-09-182020-11-0343Bladder Cancer
NCT03376659Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic AdenocarcinomaTerminatedPhase 1/22018-08-082021-08-308Colorectal Adenocarcinoma; Metastatic Colorectal Cancer; Metastatic Pancreatic Cancer; Pancreatic Adenocarcinoma
NCT03547999A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRCTerminatedPhase 22018-06-262024-03-1317Metastatic Colorectal Cancer
NCT03315871Combination Immunotherapy in Biochemically Recurrent Prostate CancerCompletedPhase 22018-03-202024-06-0440Prostate Cancer
NCT02840994A Trial of CV301 in Combination With Anti-PD-1 Therapy in Subjects With Non-Small Cell Lung CancerCompletedPhase 12016-122020-0124Non-small Cell Lung Cancer (NSCLC)
Unconfirmed matches (5)

Trials that mention one of the names in a weaker way (a code only in the title, a short or ambiguous name). Not counted above.

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditionsMatched by
NCT02015104Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCGCompletedPhase 22013-12-182018-09-1832Bladder Cancerintervention named: PANVAC
NCT00669734Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By SurgeryActive not recruitingPhase 12010-02-012021-09-0218Locally Advanced Pancreatic Adenocarcinoma; Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Stage III Pancreatic Cancer AJCC v6 and v7; Stage IV Pancreatic Cancer AJCC v6 and v7name in intervention: PANVAC
NCT00179309Docetaxel Alone or in Combination With Vaccine to Treat Breast CancerCompletedPhase 22005-092013-0248Breast Cancername in intervention: PANVAC
NCT00088413PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced CancerCompletedPhase 1/22004-07-212018-04-0151Adenocarcinoma; Breast Cancer; Colorectal Cancer; Ovarian Cancername in intervention: PANVAC
NCT00088660PANVAC™-VF Vaccine for the Treatment of Metastatic Pancreatic Cancer After Failing a Gemcitabine-Containing RegimenUnknownPhase 32004-06250Pancreatic Cancername in intervention: PANVAC

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 41520164The quadruple immunotherapy for colorectal cancer (QuICC) trial for mismatch repair-proficient metastatic colorectal cancer.The oncologist2026cited by trial NCT04491955
PMID 35998004Phase II trial of CV301 vaccine combined with atezolizumab in advanced urothelial carcinoma.Cancer immunology, immunotherapy : CII2023name in title: CV301
PMID 36054490Phase 1 trial of CV301 in combination with anti-PD-1 therapy in nonsquamous non-small cell lung cancer.International journal of cancer2023cited by trial NCT02840994
Unconfirmed matches (2)

Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.

PubMedTitleJournalYearLinked by
PMID 40781051Bacillus Calmette-Guérin (BCG) in combination with PANVAC™ vs. BCG alone in adults with high-grade BCG-refractory non-muscle-invasive bladder cancer.Urologic oncology2025name in title: PANVAC
PMID 26291768Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial.JAMA oncology2015name in title: PANVAC

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 31110074A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules.Clinical cancer research : an official journal of the American Association for Cancer Research2019name in title: CV301
PMID 31227502When Cancer Vaccines Go Viral.Clinical cancer research : an official journal of the American Association for Cancer Research2019name in abstract: CV301
Unconfirmed matches (6)

Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.

PubMedTitleJournalYearLinked by
PMID 22380820Outlining novel scenarios for improved therapeutic cancer vaccines: the PANVAC paradigm.Expert review of vaccines2012name in title: PANVAC
PMID 22892452Induction of antitumor immunity ex vivo using dendritic cells transduced with fowl pox vector expressing MUC1, CEA, and a triad of costimulatory molecules (rF-PANVAC).Journal of immunotherapy (Hagerstown, Md. : 1997)2012name in title: PANVAC
PMID 17373905PANVAC-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma.Expert opinion on biological therapy2007name in title: PANVAC
PMID 16451103Development of the PANVAC-VF vaccine for pancreatic cancer.Expert review of vaccines2006name in title: PANVAC
PMID 16512998A phase II study of active immunotherapy with PANVAC or autologous, cultured dendritic cells infected with PANVAC after complete resection of hepatic metastases of colorectal carcinoma.Clinical colorectal cancer2006name in title: PANVAC
PMID 16800982A randomized phase II study of docetaxel alone or in combination with PANVAC-V (vaccinia) and PANVAC-F (fowlpox) in patients with metastatic breast cancer (NCI 05-C-0229).Clinical breast cancer2006name in title: PANVAC

NIH grants

ProjectTitleOrganisationPIYearsLinked by
ZIABC010598Human Immune Responses to Tumor Antigens for Cancer ImmunotherapyDIVISION OF BASIC SCIENCES - NCISCHLOM, JEFFREY2012–2025name in abstract: MVA-BN-CV301
ZIABC011906CV301 and Anti-PD-1 Therapy in Non-Small Cell Lung CancerDIVISION OF BASIC SCIENCES - NCIRAJAN, ARUN2019–2025name in title: CV301
ZIDDC000075NIDCD Core for Clinical Research and CareNATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSLEVY, JOSHUA2021–2025name in abstract: CV301
ZIABC010425Strategies for Cancer Immunotherapy Clinical TrialsDIVISION OF BASIC SCIENCES - NCISCHLOM, JEFFREY2009–2023name in abstract: MVA-BN-CV301
ZIABC011547Cancer Immunotherapy Clinical TrialsDIVISION OF BASIC SCIENCES - NCISTRAUSS, JULIUS2014–2022name in abstract: MVA-BN-CV301
ZIABC011865Breast and Other Carcinoma Clinical Trials Using ImmunotherapiesDIVISION OF BASIC SCIENCES - NCIGATTI-MAYS, MARGARET2019–2020name in abstract: MVA-BN-CV301

Notes

MVA-BN-CV301 prime (NCIt C143059) with FPV-CV301 boosts (NCIt C141298), encoding CEA, MUC-1 and TRICOM: the PANVAC antigen cassette rebuilt on the non-replicating MVA-BN backbone, hence a separate program from PANVAC (AXP000142). Phase 1/2 in NSCLC and bladder cancer with checkpoint inhibitors (Bavarian Nordic-sponsored). Originator/sponsor taken from the MVA-BN naming in NCIt and Bavarian Nordic press coverage; not independently confirmed here.

How to cite

CV301 (AXP000180.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000180.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.